Abstract:BACKGROUND: Per- and polyfluoroalkyl substances (PFAS) are persistent and ubiquitous environmental contaminants with well-documented hepatotoxicity. However, the mechanistic linkage between PFAS exposure and non-alcoholic fatty liver disease (NAFLD) remains largely elusive.OBJECTIVES: This study aimed to explore PFAS-to-NAFLD link and the relevant molecular mechanisms.METHODS: The cross-sectional analyses using National Health and Nutrition Examination Survey (NHANES) data were conducted to investigate the association between PFAS exposure and NAFLD. A combination of in silico toxicological analyses, bioinformatics approaches, animal experiments, and in vitro assays was used to explore the molecular initiating events (MIEs) and key events (KEs) in PFAS-induced hepatic lipid metabolism disorders.RESULTS: The cross-sectional analyses with NHANES data revealed the significant association between PFAS exposure and hepatic steatosis/NAFLD. The in silico toxicological analyses showed that PPARα activation induced by perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS), prototypical representatives of PFAS, is the critical MIE associated with NAFLD-predominant liver diseases. Transcriptome-based bioinformatic annotation and analyses identified that transcriptional upregulation of hepatic acyl-CoA oxidase 1 (ACOX1) in PPARα-regulated peroxisomal β-oxidation pathway was the KE involved with PFOA/PFOS-perturbed hepatic lipid metabolic pathways in humans, mice and rats. The in vivo and in vitro assays further verified that ACOX1-mediated oxidative stress contributed to mitochondrial compromise and lipid accumulation in PFOA/PFOS-exposed mouse hepatocytes, which could be mitigated by co-treatment with ACOX1 inhibitor and mitochondria ROS scavenger. Additionally, we observed that besides PFOA and PFOS, hepatic ACOX1 exhibited good-fit response to short-term exposures of long-chain (C7-C10) perfluoroalkyl carboxylic acids (PFHpA, PFNA, PFDA) and perfluoroalkyl sulfonic acids (PFHpS, PFDS) in human hepatocyte spheroids through benchmark dose (BMD) modeling.CONCLUSION: Our study unveils a novel molecular target for PFAS-induced hepatic lipid metabolic disorders, shedding new light on prediction, assessment, and mitigation of PFAS hepatotoxicity.

A structural basis for the activation of peroxisome proliferator-activated receptor gamma (PPARγ) by perfluorooctanoic acid (PFOA)

Structure-dependent binding and activation of perfluorinated compounds on human peroxisome proliferator-activated receptor γ

Activation of human nuclear receptors by perfluoroalkylated substances (PFAS)

PFOA regulate adenosine receptors and downstream concentration-response cAMP-PKA pathway revealed by integrated omics and molecular dynamics analyses

PFO5DoDA disrupts hepatic homeostasis primarily through glucocorticoid signaling inhibition

Relationship between peroxisome proliferator-activated receptor alpha activity and cellular concentration of 14 perfluoroalkyl substances in HepG2 cells

PPARα/ACOX1 as a novel target for hepatic lipid metabolism disorders induced by per- and polyfluoroalkyl substances: An integrated approach

Low‐level Perfluorooctanoic Acid Enhances 3 T3‐L1 Preadipocyte Differentiation Via Altering Peroxisome Proliferator Activated Receptor Gamma Expression and Its Promoter DNA Methylation

Perfluorooctanoic acid (PFOA) and its alternative perfluorobutanoic acid (PFBA) alter hepatic bile acid profiles via different pathways

Perfluorooctanoic acid (PFOA) affects distinct molecular signalling pathways in human primary hepatocytes

Perfluorooctanoate (PFOA) cell-autonomously promotes thermogenic and adipogenic differentiation of brown and white adipocytes

Molecular mechanisms of PFOA-induced toxicity in animals and humans: Implications for health risks

Metabolomic Analysis Reveals Metabolic Alterations of Human Peripheral Blood Lymphocytes by Perfluorooctanoic Acid.

Activation of sterol regulatory element-binding proteins in mice exposed to perfluorooctanoic acid for 28 days

An integrated metabonomics and transcriptomics approach to understanding metabolic pathway disturbance induced by perfluorooctanoic acid.

Perfluorooctanoic acid induces gene promoter hypermethylation of glutathione-S-transferase Pi in human liver L02 cells.

Biphasic effects of perfluorooctanoic acid on steroidogenesis in mouse Leydig tumour cells.

A novel molecular pathway of lipid accumulation in human hepatocytes caused by PFOA and PFOS

Effect of PFOA on DNA Methylation and Alternative Splicing in Mouse Liver

Environment Relevant Exposure of Perfluorooctanoic Acid Accelerates the Growth of Hepatocellular Carcinoma Cells Through Mammalian Target of Rapamycin (mtor) Signal Pathway.

Evaluating the mode of action of perfluorooctanoic acid-induced liver tumors in male Sprague-Dawley rats using a toxicogenomic approach